+33 (0) 4 76 45 21 20 contact@sb-peptide.com
Sélectionner une page

Tumor-Associated Antigens – Cancer research peptides

Tumor-associated antigens (TAAs) act as target peptides to induce cytotoxic T lymphocyte (CTL) responses for the development of cancer vaccines, a promising approach for cancer immunotherapy.
Tumor-associated antigens are selected based on their, immunogenicity, role in oncogenicity, number of antigenic epitopes and their expression level in antigen-positive cancer cells1.
Receptors of CD8+ T cells usually recognize antigenic peptides presented in association with MHC class I molecules. Peptides displayed on the HLA-A*0201 molecules are the most frequently used since this HLA allele (HLA-A group, MHC class I) is expressed by 45% of the human population and the peptide binding motifs are well-charaterized1.
To validate the efficacy of a tumor-associated antigen as a T-cell epitope, CD8+ T cells are usually induced in vitro using peptide-pulsed dendritic cells (DCs), generated from peripheral blood mononuclear cells (PBMCs), as antigen-presenting cells (APCs). Upon primary in vitro immunization, peptide-responding T cells are analyzed for their capacity to recognize tumor cell lines expressing the candidate tumor-associated antigen and to trigger an antigen-specific and HLA-A*02-restricted cytolytic activity against the target tumor cells. This approach is nammed reverse immunology. It has been successfully used to identify several antigenic peptides that are recognized by CD4+ or CD8+ T lymphocytes.
Tumour-associated antigens that have the potential to elicit immune responses are classified into different categories2 :

  • Antigens of high tumoural specificity
    Antigens derived from oncogenic viruses
    Antigens encoded by mutated genes
    Antigens encoded by cancer-germline genes
  • Antigens of low tumoural specificity
    Tissue/Lineage-restricted differentiation antigens
    Antigens derived from overexpressed proteins

 

Name Description Catalog # More details
Melan-A / MART1 (26-35) peptide Tumor-associated antigen peptide SB026 Click here
MUC1 (12-20) peptide Tumor-associated antigen peptide SB027 Click here
OVA 257-264 Tumor-associated antigen peptide SB031 Click here
PADRE peptide Tumor-associated antigen peptide SB054 Click here